Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 8/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30443506 | 0.85 | HASPIN (0.49) | HASPINHTTKDM4EALDH1A1NCOA1 | |
| SCHEMBL30165118 | 0.84 | HASPIN (0.42) | HASPINHTTKDM4EALDH1A1NCOA1 | |
| SCHEMBL159102 | 0.76 | KDM4E (0.44) | HTTKDM4EALDH1A1NTRK1MEN1 | |
| SCHEMBL29937346 | 0.76 | KDM4E (0.44) | HTTKDM4EALDH1A1NTRK1MEN1 | |
| SCHEMBL12045583 | 0.74 | KDM4E (0.39) | HASPINHTTKDM4EALDH1A1NCOA1 | |
| SCHEMBL23554440 | 0.71 | ROCK2 (0.36) | HASPINKDM4EALDH1A1CSNK1DDYRK1A | |
| SCHEMBL10982628 | 0.71 | MEN1 (0.40) | HASPINKDM4EALDH1A1NTRK1RPS6KA5 | |
| SCHEMBL15565637 | 0.70 | CYP2A6 (0.40) | HASPINHTTKDM4EALDH1A1NTRK1 | |
| SCHEMBL3046801 | 0.70 | MAPT (0.40) | HASPINHTTKDM4EALDH1A1NTRK1 | |
| SCHEMBL17652985 | 0.70 | ALDH1A1 (0.44) | HASPINHTTKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151594-A1 | FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| EP-4228632-A2 | REV-ERB AGONISTS | Saint Louis University (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116635029-A | REV-ERB agonists | 圣路易斯大学 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022093552-A9 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022093552-A9 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022093552-A2 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093552-A2 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-05-05 | — | — | WO | disclosed |
| US-10494378-B2 | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2019-12-03 | — | — | US | disclosed |
| EP-3354653-B1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD (CN) | 2019-09-04 | — | — | EP | disclosed |
| EP-3354653-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | Guangzhou Maxinovel Pharmaceuticals Co. Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-9725462-B2 | Pyridopyrimidine derivatives as protein kinase inhibitors | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| WO-2017012559-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | 广州再极医药科技有限公司 | 2017-01-26 | — | — | WO | disclosed |
| EP-2882746-B1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-12-07 | — | — | EP | disclosed |
| EP-2882746-B1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-12-07 | — | — | EP | disclosed |
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-08-06 | — | — | US | disclosed |
| EP-2882746-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Merck Patent GmbH (DE) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023385-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014023385-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10494378-B2 | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | FLT3, FGFR1, FGFR3 | HASPIN 3080/4885HTT 2980/4885KDM4E 1602/4885 |
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SYK, LYN, IRAK1 | HASPIN 1212/4885HTT 4739/4885KDM4E 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.